Neurocrine Biosciences, based in San Diego, develops pharmaceuticals for neurological disorders and employs 1,448 people. Its FDA-approved products include INGREZZA and Orilissa, with a strong clinical development pipeline.
Ingrid Delaet sold 457 shares of NBIX on 10 July at $135.00 per share, worth a total of $62K. They now own 4,730 NBIX shares, or a 9% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
